poduim dark 1
Podium to PracticeTM is an exclusive accredited continuing education activity featuring two experts as they provide key summary and guidance on the optimal use of current and emerging therapies and interpretation of data.

Podium to Practice

Recent Updates on the Treatment of Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

Highlights from the 2021 Hematology Annual Meeting

PIM logo COLOR 01
Mascarenhas John


John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Vannucchi Alessandro Maria


Alessandro Vannucchi, MD

Professor of Hematology Careggi University Hospital University of Florence Florence, Italy

Clinical Updates for the Treatment of Patients with CLL

BTK Inhibitors
BCL2 Inhibitors

Updates from the 2021 Annual Hematology Meeting

PIM logo COLOR 01
Woyach Jennifer


Jennifer Woyach, MD

Associate Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Davids Matthew


Matthew S. Davids, MD MMSc

Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute, Boston, Massachusetts

Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting

Breast Cancer

2021 San Antonio Breast Cancer Symposium

PIM logo COLOR 01
Hurvitz Sara


Sara Huvitz, MD, FACP

Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center
Los Angeles, California

Tolaney Sara


Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

Data Updates from the 2021 Annual Hematology Meeting That Will Impact the Treatment of Patients with Indolent and Aggressive Lymphomas

Indolent and Aggressive Lymphoma

2021 Annual Hematology Meeting

Lunning Matthew


Matthew Lunning, DO, FASCO

Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska

Kamdar Manali


Manali Kamdar, MD

Associate Professor
Clinical Director of Lymphoma Services
Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation
University of Colorado Cancer Center
Aurora, Colorado

Updates in the Treatment of DLBCL From Chemotherapy to Novel Targeted Therapies

Diffuse B-Cell Lymphoma

Updates from the 2021 ASCO, EHA, and ICML Annual Meetings.

Kline Justin


Justin Kline, MD

Director, Lymphoma Program
Associate Professor of Medicine
University of Chicago Medicine
Chicago, Illinois

Sehn Laurie


Laurie Sehn, MD

Clinical Assistant Professor, Division of Medical Oncology
The University of British Columbia
Vancouver, British Columbia

Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data

Multiple Myeloma

Updates from the 2021 ASCO and EHA Annual Meetings

Gasparetto Cristina


Cristina Gasparetto, MD

Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Mateos Maria Victoria


Maria-Victoria Mateos, MD, PhD

Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain